Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin/fosfomycin inhalation

Drug Profile

Tobramycin/fosfomycin inhalation

Alternative Names: Corus 1040; GS 9310/11; Inhaled fosfomycin/tobramycin

Latest Information Update: 24 Feb 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Aminoglycosides; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Bronchiectasis; Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 19 Feb 2014 Tobramycin/fosfomycin inhalation licensed to CURx Pharmaceuticals worldwide
  • 08 Mar 2010 Gilead Sciences completes a phase II trial in Cystic fibrosis-associated respiratory tract infections in USA
  • 18 Oct 2007 Phase-II clinical trials in Bronchiectasis (Cystic fibrosis related) (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top